Although we discovered the SLC3A2-NRG1 fusion in a pan-negative lung adenocarcinoma detected by conventional Sanger sequencing, we performed targeted cancer panel deep sequencing to identify possible coexistence with known mutations. This evidence concerns the gene SLC3A2 and cancer.